Skip to main navigation Skip to search Skip to main content

Real-world adherence and evidence of subcutaneous and sublingual immunotherapy in grass and tree pollen-induced allergic rhinitis and asthma

  • Christian Vogelberg*
  • , Bernd Brüggenjürgen
  • , Hartmut Richter
  • , Marek Jutel
  • *Corresponding author for this work
  • Division of Hematology and Hemostaseology, Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany
  • zeb.business school, Steinbeis University Berlin, Münster, Germany
  • IQVIA Inc.
  • Medical University of Warsaw
  • Wrocław Medical University

Research output: Contribution to journalArticleAcademicpeer-review

75 Downloads (Pure)

Abstract

Purpose: Allergen immunotherapy (AIT), when continued for 3 years, is the only diseasemodifying treatment for AR and asthma. Adherence is a key to ensure effectiveness, and poor adherence is a contraindication for AIT. The objective of this study was to evaluate realworld adherence to AIT with subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) preparations in patients allergic to grass or tree pollen. The impact of AIT on the consumption of asthma and rhinitis medication was also analyzed. Patients and Methods: In this retrospective cohort analysis of a German longitudinal prescription database, the adherence of a grass and tree pollen allergoid was examined and compared to two sublingual AIT tablets/drops. Patients receiving grass or tree allergen-specific immunotherapy prescriptions were compared with non-AIT patients receiving symptomatic allergic rhinitis (AR) and asthma prescriptions. The study endpoints included therapy adherence, AR progression, and asthma progression. Multivariate regression analyses were used to estimate the effects of SCIT or SLIT, adjusting for variables related to demographics and prescriptions. Results: SCIT adherence was 60.1-61.8% at 2 years and 35.0-37.5% at 3 years for the two allergens. SLIT adherence was distinctly lower (29.5-36.5% and 9.6-18.2%, respectively). Adherence in children was higher compared to adolescents or adults. All products were highly efficacious at reducing symptomatic AR medication consumption. SCIT also reduced asthma medication use for both allergens, whereas for SLIT these results were significant only for grasses but not trees. Conclusion: Subcutaneous AIT in a real-world setting achieved significantly higher adherence rates compared to sublingual administration. SCIT reduced the use of rhinitis and asthma medication significantly for both allergens, while SLIT reduced the use of rhinitis medication for both allergens and the use of asthma medication for grasses only.
Original languageEnglish
Pages (from-to)817-827
JournalPatient preference and adherence
Volume14
DOIs
Publication statusPublished - 2020
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Real-world adherence and evidence of subcutaneous and sublingual immunotherapy in grass and tree pollen-induced allergic rhinitis and asthma'. Together they form a unique fingerprint.

Cite this